Jonathan Garen, formerly chief business officer at Syros Pharmaceuticals Inc, has been appointed chief business officer at uniQure NV, which is developing gene therapies for human use. uniQure’s therapy Glybera, was the first gene therapy to be approved for marketing in the west.
Mr Garen has also been assistant vice president for business development at Forest Laboratories Inc and director of global licencing at Pharmacia Corporation, which is now part of Pfizer Inc. In his new job he will be responsible for business development and alliance management. Mr Garen holds a Master’s Degree in environmental science from Yale University, and a Bachelor of Science degree in physics from the Massachusetts Institute of Technology.
uniQure announced the appointment on 7 July 2016.
Copyright 2016 Evernow Publishing Ltd